CARSGEN-B Reports 2025 Financial Results: Shareholder Loss Narrows Significantly

Stock News03-06

CARSGEN-B (02171) announced its annual results for the period ending December 31, 2025. The company recorded revenue of RMB 126 million, representing a year-on-year increase of 218.7%. The loss attributable to owners of the parent amounted to RMB 97.861 million, narrowing by 87.7% compared to the previous year. The basic loss per share was RMB 0.18.

During the fiscal year ending December 31, 2025, the group's revenue was primarily derived from its product CYTEZAN® (an autologous BCMA CAR-T cell therapy). It is important to note that the primary revenue recognized for CYTEZAN® is based on the ex-factory price, not the final market price. The group recognizes revenue upon completion of the ex-factory delivery of its products. Due to the necessary production cycle time for CAR-T therapies, a discrepancy exists between the number of orders received from East China Pharmaceutical and the quantity of products actually delivered from the factory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127125397?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127125397","market":"us","top_or_hot":-1,"title":"CARSGEN-B Reports 2025 Financial Results: Shareholder Loss Narrows Significantly","media":"Stock News","content":"<p>CARSGEN-B (02171) announced its annual results for the period ending December 31, 2025. The company recorded revenue of RMB 126 million, representing a year-on-year increase of 218.7%. The loss attributable to owners of the parent amounted to RMB 97.861 million, narrowing by 87.7% compared to the previous year. The basic loss per share was RMB 0.18.</p>\n<p>During the fiscal year ending December 31, 2025, the group's revenue was primarily derived from its product CYTEZAN® (an autologous BCMA CAR-T cell therapy). It is important to note that the primary revenue recognized for CYTEZAN® is based on the ex-factory price, not the final market price. The group recognizes revenue upon completion of the ex-factory delivery of its products. Due to the necessary production cycle time for CAR-T therapies, a discrepancy exists between the number of orders received from East China Pharmaceutical and the quantity of products actually delivered from the factory.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B Reports 2025 Financial Results: Shareholder Loss Narrows Significantly</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B Reports 2025 Financial Results: Shareholder Loss Narrows Significantly\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-06 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSGEN-B (02171) announced its annual results for the period ending December 31, 2025. The company recorded revenue of RMB 126 million, representing a year-on-year increase of 218.7%. The loss attributable to owners of the parent amounted to RMB 97.861 million, narrowing by 87.7% compared to the previous year. The basic loss per share was RMB 0.18.</p>\n<p>During the fiscal year ending December 31, 2025, the group's revenue was primarily derived from its product CYTEZAN® (an autologous BCMA CAR-T cell therapy). It is important to note that the primary revenue recognized for CYTEZAN® is based on the ex-factory price, not the final market price. The group recognizes revenue upon completion of the ex-factory delivery of its products. Due to the necessary production cycle time for CAR-T therapies, a discrepancy exists between the number of orders received from East China Pharmaceutical and the quantity of products actually delivered from the factory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1127125397","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127125397","pubTimestamp":1772799138,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) announced its annual results for the period ending December 31, 2025. The company recorded revenue of RMB 126 million, representing a year-on-year increase of 218.7%. The loss...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","BK1587":"次新股","02171":"科济药业-B","BK1585":"昨日强势股"},"translate_title":"科济康-B公布2025年财务业绩：股东亏损大幅收窄","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARSGEN-B (02171) announced its annual results for the period ending December 31, 2025. The company recorded revenue of RMB 126 million, representing a year-on-year increase of 218.7%. The loss attributable to owners of the parent amounted to RMB 97.861 million, narrowing by 87.7% compared to the previous year. The basic loss per share was RMB 0.18.\nDuring the fiscal year ending December 31, 2025, the group's revenue was primarily derived from its product CYTEZAN® (an autologous BCMA CAR-T cell therapy). It is important to note that the primary revenue recognized for CYTEZAN® is based on the ex-factory price, not the final market price. The group recognizes revenue upon completion of the ex-factory delivery of its products. Due to the necessary production cycle time for CAR-T therapies, a discrepancy exists between the number of orders received from East China Pharmaceutical and the quantity of products actually delivered from the factory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127125397","isCrawlerRequest":true}